The Food and Drug Administration (FDA) was advised on Tuesday to authorize Pfizer’s COVID-19 vaccine for children between the ages of 5 and 11. The FDA’s Vaccines and Related Biological Products Advisory Committee made the recommendation. Seventeen panel members voted yes to recommend the authorization. One abstained. The vote came after lengthy presentations and discussions about whether the benefits of the jab outweigh the risks for young children. Pfizer and FDA experts were unable to say the vaccine can prevent transmission of the CCP (Chinese Communist Party) virus, which causes COVID-19. But they said it will lower the risk of severe disease, hospitalization, and death among the children, citing data from trials run by Pfizer and the effectiveness of the vaccine in older age groups, who have been getting it for months. “The evidence is pretty clear that this vaccine has worked well,” Dr. Jay Portnoy, a professor of pediatrics at Children’s Mercy …